Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females by unknown
Wagner et al. Infectious Agents and Cancer  (2015) 10:13 
DOI 10.1186/s13027-015-0008-ySHORT REPORT Open AccessGlobal availability of data on HPV genotype-
distribution in cervical, vulvar and vaginal disease
and genotype-specific prevalence and incidence
of HPV infection in females
Monika Wagner1*, Liga Bennetts1, Harshila Patel1, Sharon Welner1, Silvia de Sanjose3,4 and Thomas W Weiss2Abstract
Background: Country-level HPV genotyping data may be sought by decision-makers to gauge the genotype-specific
burden of HPV-related diseases in their jurisdiction and assess the potential impact of HPV vaccines. We investigated, by
country, the availability of published literature on HPV genotypes in cervical, vaginal and vulvar cancers and
intraepithelial neoplasms (CINs, VaINs and VINs) and on prevalence and incidence of genital HPV infections
among women without clinically manifest disease.
Findings: Primary sources of publications were the PubMed/Medline and EMBASE databases. Original studies or
meta-analyses published from 2000, covering genotypes 16 and 18 and at least one of genotypes 31/33/45/52/58,
were included. Key exclusion criteria were language not English, cervical lesions not histologically confirmed (cytology
only), special populations (e.g., immunocompromised) and, for cervical studies, small population (<50). A total of 727
studies reporting HPV genotype-specific data were identified: 366 for cervical cancers and CINs, 43 for vulvar or vaginal
cancers and VINs/VaINs, and 395 and 21 for infection prevalence and incidence, respectively, in general female
population samples. A large proportion of studies originated from a small set of countries. Cervical cancer/CIN
typing data was scarce for several regions with the highest cervical cancer burden, including Eastern, Middle and
Western Africa, Central America, South-East Asia, South Asia, and Eastern Europe. Data for vulvar/vaginal disease
was limited outside of Europe and North America.
Conclusions: Although a large body of published HPV genotype-specific data is currently available, data gaps exist
for genotype-specific infection incidence and several world regions with the highest cervical cancer burden.
Keywords: HPV, Genotype, Geographic region, Epidemiology, Genital infection, Cervical lesions, Cervical cancerFindings
Background
Human papillomaviruses (HPV) belong to the most
prevalent sexually transmitted infections worldwide [1],
with genotypes 16, 18, 52, 58, 31, 51, and 56 among the
most frequently detected in women with normal cer-
vical cytology [2-4]. Globally, approximately 70% of
cervical cancers are attributable to genotypes 16 and/or
18, targeted by first-generation HPV vaccines (Gardasil®
and Cervarix®), and 90% to 16, 18, 31, 33, 45, 52 or 58,* Correspondence: monika.wagner@la-ser.com
1LASER Analytica, Montréal, Québec, Canada
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© 2015 Wagner et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
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unless otherwise stated.targeted by the 9-valent vaccine (Gardasil® 9) [5]. These
genotypes also contribute to the majority of HPV-
related vulvar [6-8] and vaginal cancers [7,8].
At the country level, decision-makers are likely to
seek data on the local genotype-specific burden of
HPV-related diseases for baseline information against
which the impact of HPV vaccination may be assessed.
Focusing on the 7 high-risk (HR) genotypes covered by
the 9-valent vaccine (16, 18, 31, 33, 45, 52 and 58), we
investigated, by country, the availability of published
literature on HPV genotypes in cervical, vaginal and
vulvar cancers and intraepithelial neoplasms (CINs,
VaINs and VINs) and on prevalence and incidence ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wagner et al. Infectious Agents and Cancer  (2015) 10:13 Page 2 of 6genital HPV infections among women without clinically
manifest disease.
Methods
The primary sources of data were the National Library of
Medicine’s PubMed/Medline and EMBASE databases.
Bibliographies were screened to identify additional sources
of information. The literature searches covered literature
published from 2000 to May 2014; key search terms in-
cluded epidemiology, human papillomavirus, genotyping,
cervix, vagina, vulva, and intraepithelial lesions, cancer, in
various combinations.
Publications meeting these criteria were included: original
study or meta-analysis reporting (1) HPV genotype distri-
bution in histologically confirmed CINs, VINs or VaINs or
cervical, vulvar or vaginal cancers, or (2) genotype-specific
genital HPV prevalence or incidence in women without
clinically manifest disease (i.e., general populations, screen-
ing populations, women with normal cervical cytology,
university students, convenience samples). Studies were in-
cluded if they reported on genotypes 16 and 18, and at least
one of the additional HR genotypes covered by the 9-valent
vaccine (31, 33, 45, 52, 58). Key exclusion criteria were:
publication not in English, small study (n < 50) for preva-
lence and cervical lesions/cancer studies, special popula-
tions (e.g., age <13 or >45 years, pregnant women, sex
workers, HIV-infected, immunocompromised), duplicate
publication. For each study, data was systematically ex-
tracted for country, world region, type and date of study,Figure 1 PRISMA diagram of study selection.type of population, age, lesion type, sample type and collec-
tion method, HPV assay, number of subjects with valid
HPV test results, and HPV genotyping results.
Study selection and data extraction were performed by
three investigators. One of these investigators performed
quality control for accuracy and conformity with selec-
tion criteria.
Availability of HPV genotyping data was compiled by
world region and country [9]. For HPV prevalence studies
(in women without clinically manifest disease), in addition
to all studies with at least 50 subjects, availability of stud-
ies with at least 500 subjects was assessed, as larger studies
provide more precise estimates of the prevalence of rare
HPV infections. Maps were created using StatPlanet Plus
(Version 3.21) visualization software (StatSilk, Melbourne,
Australia; http://www.statsilk.com/software/statplanet).
Results
The literature searches yielded 11,474 records, of which
1,765 were screened in full-text and 727 included (Figure 1,
Additional file 1). For full-text publications, the most com-
mon reason for exclusion was absence of HPV-genotype
specific data.
Over one third (n = 256) of all publications originated
from just six countries (China, Italy, United States, Brazil,
South Korea and Japan).
A large body of data (366 publications, Table 1) was
available for HPV genotype distribution in at least 50 cer-
vical cancers or CINs, with ten or more studies identified
Table 1 Distribution of included publications by world region and type of data*
Category of HPV
type-specific data
Africa Asia/Pacific Europe Latin America
and the Caribbean
Northern America Multiple world regions Globally
Any 62 236 236 104 74 19 727
Genital prevalence 38 123 126 65 39 7 395
Genital incidence 4 3 5 3 6 0 21
Cervical lesions or cancers 30 142 107 52 25 11 366
Vulvar or vaginal lesions or
cancers
1 4 23 2 9 4 43
Note: Sums of individual columns or rows exceed the total because several publications reported on multiple world regions or types of data.
*Including meta-analyses.
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Spain, South Korea, Thailand, Taiwan, the United States)
(Figure 2). Conversely, no or few (0–2) such studies
were identified for Central and Western Asia, most of
Africa, particularly Central Africa, and several countries
in Europe (mainly Eastern Europe), in Latin America
and the Caribbean, and in South and South-East Asia.
For cervical cancer specifically, 208 publications from
73 countries were identified that reported HPV geno-
type distribution in at least 50 cases (Figure 3), and four
countries (China, Japan, South Korea and the United
States) had ten or more such publications. Among the
10 most populous countries, substantial cervical cancer
data (≥8 publications) was available for China, the
United States, Japan, India, and Brazil, but very limited
data (0–2 publications) for Indonesia, Pakistan, Nigeria,
Bangladesh and Russia (Figure 3).
Forty-three publications were retrieved for vulvar and
vaginal cancers and VINs/VaINs. More than half (n = 23)
of these studies originated from Europe, with very few
available from Africa, Asia/Pacific and Latin AmericaFigure 2 Number of publications, by country, reporting HPV genotype dist
(CINs) or cervical cancers. Original studies published between January 2000
18 and at least one of genotypes 31, 33, 45, 52 or 58; ≥50 subjects with va
intraepithelial lesion.and the Caribbean (Table 1). Among four studies report-
ing vulvar and vaginal data across world regions, two
were meta-analyses [7,8], pooling already existing data,
and two were cross-sectional studies that generated new
data but did not report country-specific findings [6,10].
A total of 395 publications reported HPV genotype-
specific genital prevalence among women without clinic-
ally manifest disease. (Most of these referred to cervical
infections and a small number to vaginal infections.) For
ten countries, including Brazil and Turkey, ten or more
such publications were available (Figure 4). However, few
publications (0–2) were identified for most countries in
Africa (except for those in Eastern Africa as well as
Nigeria, Senegal and South Africa), Western Asia, Central
Asia, South Asia (except India and Iran), South-East Asia
(except Thailand and Vietnam), and Eastern Europe.
A total of 238 larger prevalence studies, reporting
genotype-specific prevalence in at least 500 subjects
without clinically manifest disease, were identified for
68 countries, which, however, excluded most countries
in Africa (Figure 5), a finding similar to an earlier reportribution in at least 50 cases of histologically confirmed cervical lesions
and May 2014; reporting prevalence data for HPV genotypes 16 and
lid HPV test results; full-text English language publication. CIN: cervical
Figure 3 Number of publications, by country, reporting HPV genotype distribution in at least 50 cases of histologically confirmed cervical cancers. Original
studies published between January 2000 and May 2014; reporting prevalence data for HPV genotypes 16 and 18 and at least one of genotypes 31, 33, 45,
52 or 58; ≥50 subjects with valid HPV test results; full-text English language publication.
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studies were identified for Central Asia and some coun-
tries in Latin America and the Caribbean, Europe, and
Asia (Figure 5).
Only 21 publications were identified that reported
type-specific incidence data in women without clinically
manifest disease, 3 to 6 per world region (Table 1).
Discussion and conclusions
Although region- or country-specific differences with re-
spect to individual HPV genotypes exist, a solid body of
research indicates that in every world region, taken to-
gether, genotypes 16/18/31/33/45/52/58 are responsibleFigure 4 Number of publications, by country, reporting HPV genotype-specific
disease*. Original studies published between January 2000 and May 2014; repor
genotypes 31, 33, 45, 52 or 58; ≥50 subjects with valid HPV DNA test resu
screening populations, women with normal cervical cytology, or conveniefor approximately 90% of cervical cancers [12,13]. Never-
theless, decision-makers may seek local data to confirm
that certain, maybe less common, vaccine-targeted geno-
types circulate in their population, to assess the potential
public health impacts of different HPV vaccination op-
tions, or to monitor the outcomes of vaccination pro-
grams in their jurisdiction.
Addressing this need, this study has uncovered a
large body of published type-specific data but has also
identified significant gaps for several world regions,
including those with the highest age-standardized inci-
dence rates of cervical cancer (ASR). Sub-regions that
have a notable scarcity of cervical cancer/CIN genotypinggenital prevalence among at least 50 women without clinically manifest
ting prevalence data for HPV genotypes 16 and 18 and at least one of
lts; full-text English language publication. *General populations,
nce samples.
Figure 5 Number of publications, by country, reporting HPV genotype-specific genital prevalence among at least 500 women without clinically
manifest disease*. Original studies published between January 2000 and May 2014; reporting prevalence data for HPV genotypes 16 and 18 and at least
one of genotypes 31, 33, 45, 52 or 58; ≥500 subjects with valid HPV DNA test results; full-text English language publication. *General populations, screening
populations, women with normal cervical cytology, or convenience samples.
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mated by GLOBOCAN 2012 [4], include Eastern Africa
(ASR per 100,000 women-years = 42.7), Middle Africa
(30.6), Western Africa (29.3), Central America (23.5),
South-Eastern Asia (16.3), South-Central Asia includ-
ing India (19.3), and Central and Eastern Europe (16.3).
An additional three sub-regions (Southern Africa, the
Caribbean, and South America) have high cervical can-
cer ASRs (>20) but only a moderate quantity of typing
data. There was also scarcity of data for vulvar/vaginal
disease, outside of Europe and North America. Glo-
bally, cervical cancer ASRs are higher in less developed
(15.7) compared to more developed regions (9.9) [4].
Clearly, most regions with the largest discrepancy be-
tween cervical cancer burden and availability of geno-
typing data belong to the less developed subset, where
lack of screening and treatment of CIN are major
drivers of cervical cancer incidence, and limited re-
search infrastructure and funding are barriers for con-
ducting HPVgenotyping studies [14].
An additional finding is that, although there may be
ample cervical lesion typing and prevalence data in
many jurisdictions, genotype-specific incidence data is
limited to few available prospective studies. Data,
such as age-specific rates of HPV acquisition, are
needed for informing dynamic models to obtain more
accurate predictions of the population health impact
of vaccination.
This study has both strengths and limitations. We
did not include anal disease in our study, as anal can-
cer affects both genders and we intended to focus on
females. However, as the burden of anal cancer isreported to be rising in Western countries [15],
genotype-specific data on this HPV-related disease
may become more important for decision-makers.
Consistent with our objective of gauging the quantity
of type-specific HPV data available, we excluded stud-
ies that reported non-type-specific data or types 16 or
18 only, which represent a large volume of published
research in this field (see Figure 1). Also, inclusion was
limited to published, English-language, peer-reviewed
studies; thus, studies written in local languages or
published in report format, for example on government
websites, were not included. Limiting inclusion to peer-
reviewed publications guarantees a minimum level of
quality in the methods and reporting of the studies
selected for our analysis. Inclusion of data from
histologically-confirmed cervical lesions only (rather than
cytologically defined lesions) is also consistent with our
focus on higher-quality studies.
In conclusion, although a large body of HPV
genotype-specific data on distribution in CINs and cer-
vical cancers and female genital prevalence is available,
significant data gaps exist for multiple world regions as
well as for type-specific incidence.Additional file
Additional file 1: Supplementary Material. Full list of 727 references
by world region.Abbreviations
CIN: Cervical intraepithelial neoplasms; HPV: Human papillomavirus;
VaIN: Vaginal intraepithelial neoplasia; VIN: Vulvar intraepithelial neoplasia.
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